Two things:
1. 2002 patent out of UNC, patent later transferred to NIH: "Methods for producing recombinant Coronavirus"
https://patents.justia.com/patent/7279327
2. "About two months after the NIH meeting on ivermectin, the NIH announced the award NOT-TR-21–024; funding of ACTIV-6 to study the use of repurposed drugs in COVID-19. Duke Un…
2. "About two months after the NIH meeting on ivermectin, the NIH announced the award NOT-TR-21–024; funding of ACTIV-6 to study the use of repurposed drugs in COVID-19. Duke University was the only institution in the country that met the criteria for the study, according to the NIH. Funding was thus distributed on a sole source basis. The “initial investment” in the trial was later announced to be $155 million. The principal investigator of the trial was not identified initially but, in a later announcement, was identified to be Susanna Naggie, who is also a member of the NIH COVID-19 Treatment Guidelines Panel. The two positions Naggie holds clearly represent a conflict of interest. A positive recommendation on the use of the drug in COVID-19 would effectively end the clinical trial. The NIH award also raises the question of whether the prospect of the award played a role in the current recommendation on ivermectin."
Two things:
1. 2002 patent out of UNC, patent later transferred to NIH: "Methods for producing recombinant Coronavirus"
https://patents.justia.com/patent/7279327
2. "About two months after the NIH meeting on ivermectin, the NIH announced the award NOT-TR-21–024; funding of ACTIV-6 to study the use of repurposed drugs in COVID-19. Duke University was the only institution in the country that met the criteria for the study, according to the NIH. Funding was thus distributed on a sole source basis. The “initial investment” in the trial was later announced to be $155 million. The principal investigator of the trial was not identified initially but, in a later announcement, was identified to be Susanna Naggie, who is also a member of the NIH COVID-19 Treatment Guidelines Panel. The two positions Naggie holds clearly represent a conflict of interest. A positive recommendation on the use of the drug in COVID-19 would effectively end the clinical trial. The NIH award also raises the question of whether the prospect of the award played a role in the current recommendation on ivermectin."